Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CAMBRIDGE NUTRITIONAL SCIENCES PLC Regulatory Filings 2020

Sep 15, 2020

7544_dva_2020-09-15_ac377b49-10e5-4257-b6bd-5ad345d9f784.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 0901Z

Omega Diagnostics Group PLC

15 September 2020

15 September 2020

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 185,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by certain employees.

Application has been made to the London Stock Exchange for the 185,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 22 September 2020.

After Admission, the total number of Ordinary Shares in issue will be 178,678,110 and the total number of voting rights will therefore be 178,678,110. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts: 

Omega Diagnostics Group PLC Tel: 01259 763 030
Colin King, Chief Executive www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd Tel: 020 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Jamie Yexley
2 Reason for notification
a. Position/Status Operations Director
b. Initial notification/

Amendment
Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Omega Diagnostics Group Plc
b. LEI 2138007U9P4BTZTYIR92
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary shares of 4p each

ISIN: GB00B1VCP282
b. Nature of the transaction Exercise of Options followed by sale of Shares
c. Price(s) and volume(s)
Price(s) Volume(s)
86.114p 85,000
d. Aggregated information

- Aggregated Volume

- Price
85,000

 86.114p
e. Date of the transaction 22/09/2020
f. Place of the transaction London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRSFLFMIESSELU